Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.60 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20023285 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL18056640 | 0.82 | ROCK2 (0.72) | ROCK2ROCK1MAPKAPK2 | |
| SCHEMBL18038310 | 0.82 | ROCK2 (0.69) | ROCK2ROCK1MAPKAPK2 | |
| SCHEMBL18038152 | 0.82 | ROCK2 (0.71) | ROCK2ROCK1 | |
| SCHEMBL18056309 | 0.81 | ROCK1 (0.59) | ROCK2ROCK1 | |
| SCHEMBL18056639 | 0.81 | ROCK2 (1.00) | ROCK2ROCK1QPCTQPCTL | |
| SCHEMBL18056323 | 0.80 | ROCK1 (0.58) | ROCK2ROCK1 | |
| SCHEMBL29664352 | 0.79 | ROCK2 (0.67) | ROCK2ROCK1 | |
| SCHEMBL20023284 | 0.79 | ROCK2 (0.67) | ROCK2ROCK1 | |
| SCHEMBL18038314 | 0.79 | ROCK2 (1.00) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| WO-2016138335-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, CIT | ROCK2 2/4885ROCK1 1/4885QPCT 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.